Ming Xie
Ming Xie has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ran Liu
Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, China
2 shared publications Nan Jiang
Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, China
1 shared publicationShuanglin Jiang
School of Biology and Food Engineering, Fuyang Normal University, Fuyang, Anhui 236037, China
1 shared publicationWenyong Li
School of Biology and Food Engineering, Fuyang Normal University, Fuyang, Anhui 236037, China
1 shared publication- Xiaoli Gao
North China Petroleum Bureau General Hospital, Renqiu, China
1 shared publication - Yu Liu
Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 18 September 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 167, 115519
Acetylation in pathogenesis: Revealing emerging mechanisms and therapeutic prospects
- 18 September 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 167, 115519
Open AccessAcetylation in pathogenesis: Revealing emerging mechanisms and therapeutic prospects
- 6 January 2021
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 14 (4) , 744-753
Predictive Value of Circulating microRNA-134 Levels for Early Diagnosis of Acute Pulmonary Embolism: Meta-analysis
Acute pulmonary embolism (APE) is a common sudden venous thromboembolism with high rates of morbidity and mortality. Several studies have concluded that microRNA-134 could be a potential biomarker for APE. However, the sensitivity of these studies varies widely. This study aimed to evaluate the diagnostic value of circulating microRNA-134 levels for APE. Four databases were searched to retrieve articles focusing on microRNA-134 detection in APE diagnosis. The Quality Assessment of Diagnostic Accuracy Studies-2 was used to evaluate the quality of the included literature. This meta-analysis included seven studies and 383 subjects. The microRNA-134 levels in APE patients were higher than those in controls (SMD = 2.84, z = 3.69, p < 0.001). The pooled sensitivity, specificity, and diagnostic odds ratio were 0.86 (0.72–0.94), 0.75 (0.66–0.82), and 19 (7–51), respectively. The positive and negative likelihood ratios were 3.4 (2.4–4.8) and 0.18 (0.08–0.40), respectively. The area under the summary receiver operating characteristic curve was 0.81 (0.77–0.84). Circulating microRNA-134 may be a new biomarker for the diagnosis of APE, but more tests and studies are needed to further explore and prove this. Trial registration number: PROSPERO registration #CRD42020184072
- 6 January 2021
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 14 (4) , 744-753
Predictive Value of Circulating microRNA-134 Levels for Early Diagnosis of Acute Pulmonary Embolism: Meta-analysis
Acute pulmonary embolism (APE) is a common sudden venous thromboembolism with high rates of morbidity and mortality. Several studies have concluded that microRNA-134 could be a potential biomarker for APE. However, the sensitivity of these studies varies widely. This study aimed to evaluate the diagnostic value of circulating microRNA-134 levels for APE. Four databases were searched to retrieve articles focusing on microRNA-134 detection in APE diagnosis. The Quality Assessment of Diagnostic Accuracy Studies-2 was used to evaluate the quality of the included literature. This meta-analysis included seven studies and 383 subjects. The microRNA-134 levels in APE patients were higher than those in controls (SMD = 2.84, z = 3.69, p < 0.001). The pooled sensitivity, specificity, and diagnostic odds ratio were 0.86 (0.72–0.94), 0.75 (0.66–0.82), and 19 (7–51), respectively. The positive and negative likelihood ratios were 3.4 (2.4–4.8) and 0.18 (0.08–0.40), respectively. The area under the summary receiver operating characteristic curve was 0.81 (0.77–0.84). Circulating microRNA-134 may be a new biomarker for the diagnosis of APE, but more tests and studies are needed to further explore and prove this. Trial registration number: PROSPERO registration #CRD42020184072